They compared the use of 18F-choline (FCH) and 68Ga-NODAGA-MJ9 (MJ9), a bombesin analogue and GRP receptor antagonist, for PET/CT imaging in 15 patients with histologically proven prostate cancer with a mean Gleason score (GS) of 7 ± 1 (6–9) and a mean PSA level of 40 ± 73 ng/ml. This evidence concerns the gene GRP and prostate carcinoma.